Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Acro Biomedical (ACBM) Operating Expenses (2016 - 2025)

Acro Biomedical has reported Operating Expenses over the past 10 years, most recently at $16377.0 for Q4 2025.

  • Quarterly results put Operating Expenses at $16377.0 for Q4 2025, up 72.97% from a year ago — trailing twelve months through Dec 2025 was $154024.0 (up 305.77% YoY), and the annual figure for FY2025 was $154024.0, up 305.77%.
  • Operating Expenses for Q4 2025 was $16377.0 at Acro Biomedical, down from $115099.0 in the prior quarter.
  • Over the last five years, Operating Expenses for ACBM hit a ceiling of $4.0 million in Q3 2022 and a floor of $8934.0 in Q1 2025.
  • Median Operating Expenses over the past 5 years was $494209.5 (2021), compared with a mean of $1.6 million.
  • Biggest five-year swings in Operating Expenses: skyrocketed 5050.84% in 2021 and later crashed 99.74% in 2024.
  • Acro Biomedical's Operating Expenses stood at $4.0 million in 2021, then decreased by 0.12% to $4.0 million in 2022, then tumbled by 99.56% to $17401.0 in 2023, then plummeted by 45.59% to $9468.0 in 2024, then surged by 72.97% to $16377.0 in 2025.
  • The last three reported values for Operating Expenses were $16377.0 (Q4 2025), $115099.0 (Q3 2025), and $13614.0 (Q2 2025) per Business Quant data.